HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis.

Abstract
Multiple sclerosis (MS) is caused by immune-mediated damage of myelin sheath. Current therapies aim to block such immune responses. However, this blocking is not sufficiently specific and hence compromises immunity, leading to severe side effects. In addition, blocking medications usually provide transient effects and require frequent administration, which further increases the chance to compromise immunity. In this regard, myelin-specific therapy may provide the desired specificity and a long-lasting therapeutic effect by inducing myelin-specific regulatory T (Treg) cells. Tolerogenic dendritic cells (TolDCs) are one such therapy. However, ex vivo generated TolDCs may be converted into immunogenic DCs in a proinflammatory environment. In this study, we identified a potential novel myelin-specific therapy that works with immunogenic DCs, hence without the in vivo conversion concern. We showed that immunization with DCs, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase for de novo synthesis of a focally high 1,25-dihydroxyvitamin D concentration in the peripheral lymphoid tissues, induced Treg cells. In addition, such engineered DCs, when pulsed with a myelin antigen, led to myelin-specific suppression of ongoing experimental allergic encephalomyelitis (an MS animal model), and the disease suppression depended on forkhead-box-protein-P3(foxp3)+ Treg cells. Our data support a novel concept that immunogenic DCs can be engineered for myelin-specific therapy for MS.-Li, C.-H., Zhang, J., Baylink, D. J., Wang, X., Goparaju, N. B., Xu, Y., Wasnik, S., Cheng, Y., Berumen, E. C., Qin, X., Lau, K.-H. W., Tang, X. Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis.
AuthorsChih-Huang Li, Jintao Zhang, David J Baylink, Xiaohua Wang, Naga Bharani Goparaju, Yi Xu, Samiksha Wasnik, Yanmei Cheng, Edmundo Carreon Berumen, Xuezhong Qin, Kin-Hing William Lau, Xiaolei Tang
JournalFASEB journal : official publication of the Federation of American Societies for Experimental Biology (FASEB J) Vol. 31 Issue 7 Pg. 2996-3006 (07 2017) ISSN: 1530-6860 [Electronic] United States
PMID28363955 (Publication Type: Journal Article)
Copyright© The Author(s).
Chemical References
  • Antigens
  • Forkhead Transcription Factors
  • Foxp3 protein, mouse
  • 25-Hydroxyvitamin D3 1-alpha-Hydroxylase
Topics
  • 25-Hydroxyvitamin D3 1-alpha-Hydroxylase (genetics, metabolism, therapeutic use)
  • Animals
  • Antigens
  • Bone Marrow Cells
  • Cell Line
  • Cells, Cultured
  • Dendritic Cells (metabolism)
  • Encephalomyelitis, Autoimmune, Experimental (therapy)
  • Female
  • Forkhead Transcription Factors (genetics, metabolism)
  • Gene Expression Regulation, Enzymologic (immunology)
  • Lymphoid Tissue
  • Mice
  • Mice, Inbred C57BL
  • Myelin Sheath
  • T-Lymphocytes, Regulatory (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: